MUC16 and neoplasm: Additionally, high TML was also observed in tumor samples with MUC16 mutations of other immune activated tumor types (e.g., cancers of the lung, colorectal, kidney, bladder, and head and neck) in the TCGA cohort (Wilcoxon rank sum test, all P < 0.001; Supplementary Figure 5).